RNAZTransCode Therapeutics Inc
$5.26
$0.1751
(3.22%)
Mkt Cap$5.16M
Vol9,110.00
Fundamentals
Mkt Cap
$5.16M
Volume
-
52W High
$20.99
52W Low
$5.01
PE Ratio
-0.11
Avg. Volume
11,905.93
EPS (Annual)
-$52.59
Rev/Employee
$0.00
Earnings
-
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer PR Newswire BOSTON, May 27, 2026 BOSTON, May 27, 2026...
PR Newswire
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University TransCode Therapeutics Appoints Dr. Anna...
PR Newswire
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 TransCode Therapeutics Enters into Agreements for up to...
PR Newswire
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer P
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the...
PR Newswire
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development TransCode Therapeutics Announces Publication of Preclinical...
PR Newswire
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment...
PR Newswire
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma TransCode Therapeutics Announces Publication of Preclinical Data...
PR Newswire
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors...
PR Newswire
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial TransCode...
PR Newswire
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot...
PR Newswire
<
1
2
...
>
Advertisement|Remove ads.
Latest RNAZ News
ViewTransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
PR Newswire
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
PR Newswire
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
PR Newswire
Advertisement|Remove ads.